SG11202113092WA - Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent - Google Patents
Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agentInfo
- Publication number
- SG11202113092WA SG11202113092WA SG11202113092WA SG11202113092WA SG11202113092WA SG 11202113092W A SG11202113092W A SG 11202113092WA SG 11202113092W A SG11202113092W A SG 11202113092WA SG 11202113092W A SG11202113092W A SG 11202113092WA SG 11202113092W A SG11202113092W A SG 11202113092WA
- Authority
- SG
- Singapore
- Prior art keywords
- combination therapy
- drug conjugate
- antibody drug
- pi3k inhibitor
- secondary agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1908233.8A GB201908233D0 (en) | 2019-06-10 | 2019-06-10 | Combination therapy |
GBGB1908234.6A GB201908234D0 (en) | 2019-06-10 | 2019-06-10 | Combination therapy |
PCT/EP2020/065880 WO2020249528A1 (fr) | 2019-06-10 | 2020-06-08 | Polythérapie comprenant un conjugué médicament-anticorps anti-cd19 et un inhibiteur de pi3k ou un agent secondaire |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202113092WA true SG11202113092WA (en) | 2021-12-30 |
Family
ID=71103360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202113092WA SG11202113092WA (en) | 2019-06-10 | 2020-06-08 | Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220305132A1 (fr) |
EP (1) | EP3980079A1 (fr) |
JP (1) | JP2022535609A (fr) |
KR (1) | KR20220020332A (fr) |
CN (1) | CN114302745A (fr) |
AU (1) | AU2020292965A1 (fr) |
CA (1) | CA3142645A1 (fr) |
IL (1) | IL288716A (fr) |
MX (1) | MX2021015403A (fr) |
SG (1) | SG11202113092WA (fr) |
WO (1) | WO2020249528A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3216410A1 (fr) | 2021-04-21 | 2022-10-27 | Guy Dipierro | Methodes de traitement et de dosage de compositions de cellules tueuses naturelles |
WO2024028433A1 (fr) * | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Procédés de traitement de troubles lymphoprolifératifs |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
ATE504565T1 (de) | 2005-10-07 | 2011-04-15 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
EP2550975A1 (fr) * | 2011-07-29 | 2013-01-30 | Sanofi | Polythérapie pour le traitement de symptômes de malignités CD19+lymphocytes B comprenant un immunoconjugué anti-CD19 maytansinoïde et du rituximab |
CA2887899C (fr) | 2012-10-12 | 2020-03-31 | Adc Therapeutics Sarl | Conjugues anticorps anti-cd22 - pyrrolobenzodiazepine |
EP2906298B1 (fr) | 2012-10-12 | 2018-10-03 | ADC Therapeutics SA | Conjugués pyrrolobenzodiazépine-anticorps |
GB201506399D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
EP3442584B1 (fr) * | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinaisons de conjugués anticorps-médicament à base de pbd et d'inhibiteurs de bcl-2 |
EP3612839A1 (fr) * | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Polythérapie |
UA127900C2 (uk) * | 2017-06-14 | 2024-02-07 | Ейдісі Терапьютікс Са | Схема дозування для введення adc до cd19 |
EP3843748A1 (fr) * | 2018-08-31 | 2021-07-07 | ADC Therapeutics SA | Polythérapie |
WO2020109251A1 (fr) * | 2018-11-29 | 2020-06-04 | Adc Therapeutics Sa | Régime posologique |
-
2020
- 2020-06-08 SG SG11202113092WA patent/SG11202113092WA/en unknown
- 2020-06-08 WO PCT/EP2020/065880 patent/WO2020249528A1/fr unknown
- 2020-06-08 JP JP2021573165A patent/JP2022535609A/ja active Pending
- 2020-06-08 KR KR1020227000169A patent/KR20220020332A/ko unknown
- 2020-06-08 US US17/617,875 patent/US20220305132A1/en active Pending
- 2020-06-08 EP EP20733376.6A patent/EP3980079A1/fr active Pending
- 2020-06-08 MX MX2021015403A patent/MX2021015403A/es unknown
- 2020-06-08 AU AU2020292965A patent/AU2020292965A1/en active Pending
- 2020-06-08 CN CN202080042853.5A patent/CN114302745A/zh active Pending
- 2020-06-08 CA CA3142645A patent/CA3142645A1/fr active Pending
-
2021
- 2021-12-06 IL IL288716A patent/IL288716A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022535609A (ja) | 2022-08-09 |
EP3980079A1 (fr) | 2022-04-13 |
AU2020292965A1 (en) | 2022-01-27 |
IL288716A (en) | 2022-02-01 |
CA3142645A1 (fr) | 2020-12-17 |
US20220305132A1 (en) | 2022-09-29 |
WO2020249528A1 (fr) | 2020-12-17 |
CN114302745A (zh) | 2022-04-08 |
KR20220020332A (ko) | 2022-02-18 |
MX2021015403A (es) | 2022-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282727A (en) | Combination therapy that includes a KRASG12C inhibitor and one or more pharmaceutical active factors for the treatment of cancers | |
SG11202106635WA (en) | Combination of antibody-drug conjugate and kinase inhibitor | |
IL288716A (en) | Combined treatment including an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary factor | |
IL285148A (en) | Diligand drug conjugate and its use | |
IL290979A (en) | Antibody-drug conjugates containing anti-human ror1 antibody and use thereof | |
IL288717A (en) | Combined treatment that includes an anti-cd25 antibody drug conjugate and an additional substance | |
EP3890789A4 (fr) | Radioimmunoconjugués et polythérapie à base d'inhibiteur de point de contrôle | |
IL276609A (en) | Combined treatment with epilimod and glutamatergic factors | |
IL282312A (en) | Pharmaceutical compositions comprising an atr inhibitor and a dna-alkylating antibody/drug conjugate and its use | |
IL281076A (en) | Anti-CD3 folate antibody biological conjugates and uses thereof | |
EP4083069A4 (fr) | Anticorps anti-ox40 et utilisation associée | |
IL277573A (en) | Antibody conjugates of cMET monoclonal binding agents and uses thereof | |
IL256451A (en) | Combined treatment with anti-her2 antibody coupling - drug and bcl-2 inhibitor | |
IL278225A (en) | Anti SEZ6 antibody drug conjugates and methods of use | |
IL304200A (en) | Combined treatment using anti-fucosyl-gm1 antibody | |
ZA202202617B (en) | Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor | |
IL281670A (en) | Combination of PD-1 antagonist, ATR inhibitor and platinating agent for cancer treatment | |
EP3960242A4 (fr) | Conjugué et agent thérapeutique contre le cancer | |
EP3999092A4 (fr) | Agents et méthodes de polythérapie contre le cancer | |
IL308545A (en) | A medical preparation that includes an anti-CD205 antibody and an immune checkpoint inhibitor | |
EP3733204A4 (fr) | Agent thérapeutique pour incontinence urinaire de stress et incontinence fécale | |
GB201900263D0 (en) | Pleasure-enhancing contraceptive and prophy-lactic underwear | |
EP3967327A4 (fr) | Conjugué de trolox-peptide et utilisation de ce dernier | |
MX2021005936A (es) | Metodos farmaceuticos. | |
GB202113653D0 (en) | Blood procurement device |